RU2006130623A - Противоопухолевые сочетания cci-779 и ритаксимаба - Google Patents

Противоопухолевые сочетания cci-779 и ритаксимаба Download PDF

Info

Publication number
RU2006130623A
RU2006130623A RU2006130623/14A RU2006130623A RU2006130623A RU 2006130623 A RU2006130623 A RU 2006130623A RU 2006130623/14 A RU2006130623/14 A RU 2006130623/14A RU 2006130623 A RU2006130623 A RU 2006130623A RU 2006130623 A RU2006130623 A RU 2006130623A
Authority
RU
Russia
Prior art keywords
mtor inhibitor
ritaximab
cci
mammal
dose
Prior art date
Application number
RU2006130623/14A
Other languages
English (en)
Other versions
RU2389508C2 (ru
Inventor
Элиел БАЙЕВЕР (US)
Элиел БАЙЕВЕР
Лауренс МООРЕ (US)
Лауренс МООРЕ
Мэттью Л. ШЕРМАН (US)
Мэттью Л. Шерман
Ли Ф. АЛЛЕН (US)
Ли Ф. АЛЛЕН
Льюис С. СТРАУСС (US)
Льюис С. СТРАУСС
Original Assignee
Вайет (Us)
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2006130623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайет (Us), Вайет filed Critical Вайет (Us)
Publication of RU2006130623A publication Critical patent/RU2006130623A/ru
Application granted granted Critical
Publication of RU2389508C2 publication Critical patent/RU2389508C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (16)

1. Способ лечения Неходжкинской лимфомы у млекопитающего, нуждающегося в лечении, который включает введение указанному млекопитающему эффективного количества сочетания, включающего ингибитор mTOR и ритаксимаб.
2. Способ по п.1, в котором или ингибитор mTOR, ритаксимаб или оба агента водят в субтерапевтически эффективных количествах.
3. Способ по п.1 или 2, в котором ингибитором mTOR является CCI-779.
4. Способ по п.1 или 2, в котором ингибитором mTOR является рапамицин.
5. Способ по п.1 или 2, в котором ингибитором mTOR является 42-O-(2-гидрокси)этил рапамицин.
6. Применение сочетания ингибитора mTOR и ритаксимаба в приготовлении лекарства для лечения Неходжкинской лимфомы у млекопитающего.
7. Применение по п.6, где или ингибитор mTOR, или ритаксимаб, или оба агента вводят в субтерапевтически эффективных количествах.
8. Применение по п.6 или 7, где ингибитором mTOR является CCI-779.
9. Применение по п.6 или 7, где ингибитором mTOR, является рапамицин.
10. Применение по п.6 или 7, где ингибитором mTOR, является 42-O-(2-гидрокси)этил рапамицин.
11. Продукт, содержащий ингибитор mTOR и ритаксимаб в качестве комбинированного препарата для одновременного, раздельного или последовательного использования в лечении Неходжкинской лимфомы у млекопитающего.
12. Продукт по п.11, где ингибитором mTOR является CCI-779.
13. Фармацевтическая упаковка, содержащая курс лечения Неходжкинской лимфомы для одного индивидуального млекопитающего, причем упаковка содержит (а) по меньшей мере одну дозу ингибитора mTOR и (б) по меньшей мере одну дозу ритаксимаба в виде однократной дозы.
14. Фармацевтическая упаковка по п.13, где ингибитором mTOR является CCI-779.
15. Фармацевтическое сочетание, используемое в лечении Неходжкинской лимфомы у млекопитающего, включающее (а) по меньшей мере одну дозу ингибитора mTOR и (б) по меньшей мере одну дозу ритаксимаба в виде однократной дозы и фармацевтически приемлемый носитель.
16. Фармацевтическое сочетание по п.15, где ингибитором mTOR является CCI-779.
RU2006130623/14A 2004-03-11 2005-03-09 Противоопухолевые сочетания ссi-779 и ритаксимаба RU2389508C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55212204P 2004-03-11 2004-03-11
US60/552,122 2004-03-11

Publications (2)

Publication Number Publication Date
RU2006130623A true RU2006130623A (ru) 2008-04-20
RU2389508C2 RU2389508C2 (ru) 2010-05-20

Family

ID=34964832

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006130623/14A RU2389508C2 (ru) 2004-03-11 2005-03-09 Противоопухолевые сочетания ссi-779 и ритаксимаба

Country Status (21)

Country Link
US (1) US20050272758A1 (ru)
EP (1) EP1722817A1 (ru)
JP (1) JP2007528399A (ru)
KR (1) KR20070027510A (ru)
CN (1) CN1929863A (ru)
AR (1) AR047988A1 (ru)
AU (1) AU2005221675A1 (ru)
BR (1) BRPI0508451A (ru)
CA (1) CA2557005A1 (ru)
CR (1) CR8571A (ru)
EC (1) ECSP066835A (ru)
GT (1) GT200500040A (ru)
IL (1) IL177565A0 (ru)
NO (1) NO20064130L (ru)
PA (1) PA8625801A1 (ru)
PE (1) PE20060002A1 (ru)
RU (1) RU2389508C2 (ru)
SG (1) SG150559A1 (ru)
SV (1) SV2005002048A (ru)
TW (1) TW200539869A (ru)
WO (1) WO2005087265A1 (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
DE602006021142D1 (de) 2005-02-03 2011-05-19 Gen Hospital Corp Verfahren zur behandlung von gefitinib-resistentem krebs
JP2006306743A (ja) * 2005-04-26 2006-11-09 Hamamatsu Photonics Kk 体液処理方法
DK1912675T3 (en) 2005-07-25 2014-03-24 Emergent Product Dev Seattle B-cell reduction using specific and cd37-cd20-specific binding molecules
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008116163A1 (en) * 2007-03-22 2008-09-25 Oregon Health & Science University Therapeutic drug combinations for treatment of b-cell malignancies
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2368700T3 (es) 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
DK2656844T3 (en) 2008-06-17 2015-03-02 Wyeth Llc ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
CN105963313A (zh) 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
EP2358390A1 (en) * 2008-11-13 2011-08-24 Emergent Product Development Seattle, LLC Cd37 immunotherapeutic combination therapies and uses thereof
AU2010234968B2 (en) 2009-04-06 2015-05-14 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
US20130028895A1 (en) * 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
ES2313983T3 (es) * 2000-09-19 2009-03-16 Wyeth Esteres hidrosolubles de rapamicina.
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA78706C2 (en) * 2001-06-01 2007-04-25 Wyeth Corp Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
UA83484C2 (ru) * 2003-03-05 2008-07-25 Уайт Способ лечения рака молочной железы комбинацией производного рапамицина и ингибитора ароматазы - летрозола, фармацевтическая композиция
MXPA05010582A (es) * 2003-04-22 2005-11-23 Wyeth Corp Combinaciones antineoplasicas.
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto

Also Published As

Publication number Publication date
PE20060002A1 (es) 2006-02-14
BRPI0508451A (pt) 2007-07-24
SV2005002048A (es) 2005-11-04
WO2005087265A8 (en) 2006-10-05
RU2389508C2 (ru) 2010-05-20
CR8571A (es) 2007-02-05
NO20064130L (no) 2006-10-10
AR047988A1 (es) 2006-03-15
CA2557005A1 (en) 2005-09-22
JP2007528399A (ja) 2007-10-11
IL177565A0 (en) 2006-12-10
AU2005221675A1 (en) 2005-09-22
KR20070027510A (ko) 2007-03-09
WO2005087265A1 (en) 2005-09-22
SG150559A1 (en) 2009-03-30
GT200500040A (es) 2005-10-24
TW200539869A (en) 2005-12-16
EP1722817A1 (en) 2006-11-22
US20050272758A1 (en) 2005-12-08
PA8625801A1 (es) 2006-06-02
CN1929863A (zh) 2007-03-14
ECSP066835A (es) 2006-11-24

Similar Documents

Publication Publication Date Title
RU2006130623A (ru) Противоопухолевые сочетания cci-779 и ритаксимаба
Ruocco et al. Pemphigus: associations and management guidelines: facts and controversies
US11793794B2 (en) Combination therapy for treating or preventing depression or other mood diseases
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
RU2010147287A (ru) Комбинированная композиция
US8491927B2 (en) Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
BRPI0519471A2 (pt) formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
JP2006206613A (ja) 粘膜炎の処置および予防のための方法および組成物
RU2003131876A (ru) Композиции n-ацетилцистеина и способы лечения и профилактики токсичности лекарственных средств
AR028504A2 (es) Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial
JP2006504795A5 (ru)
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
JP2012505883A5 (ru)
JP2008517991A5 (ru)
RU2006101225A (ru) Пероральные лекарственные формы мемантина
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
RU2005131868A (ru) Фармацевтическая композиция, фармацевтическая комбинация (варианты) и способы их применения
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
RU2008148597A (ru) Фармацевтические комбинации
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
CA2385930A1 (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090616

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090616

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20090810

MM4A The patent is invalid due to non-payment of fees

Effective date: 20110310